ArticleOncoTargets and therapy2017
RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.Medicine · 2018Pooled it
- The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis.International journal of environmental research and public health · 2017Pooled it
- Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.PloS one · 2017Pooled it
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.Cell death discovery · 2026Review
- A comprehensive diagnostic scheme of morphological combined molecular methylation under bronchoscopy.Frontiers in oncology · 2023Article
- The Role ofJournal of clinical medicine · 2022Article
- Molecular features of aggressive thyroid cancer.Frontiers in oncology · 2022Review
- Promoter Methylation of Tumor Suppressors in Thyroid Carcinoma: A Systematic Review.Iranian journal of public health · 2021Review
- The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.Cells · 2021Review
- Prediction of the Prognosis Based on Chromosomal Instability-Related DNA Methylation Patterns of ELOVL2 and UBAC2 in PTCs.Molecular therapy. Nucleic acids · 2019Article
- Multidrug resistance affects the prognosis of primary epithelial ovarian cancer.Oncology letters · 2019Article
- A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension.Nature communications · 2019Article
- Protective effect of KLF15 on vascular endothelial dysfunction induced by TNF‑α.Molecular medicine reports · 2018Article
- DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrevious studies have reported that Ras-associated domain family 1A (RASSF1A), the most commonly silenced tumor suppressor via promoter methylation, played vital roles in the development of carcinogenesis. The purpose of this meta-analysis was to determine whether RASSF1A promoter methylation increased the risk of thyroid cancer.
methodsPubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases were searched to obtain eligible studies. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations, using Stata 12.0 software. The methodological quality of included studies was evaluated using Newcastle-Ottawa scale table. Egger's test and Begg's test were applied to detect publication biases. TSA 0.9 software was used to calculate the required information size and whether the result was conclusive.
resultsA total of 10 articles with 12 studies that included 422 thyroid cancer patients, identifying the association of RASSF1A promoter methylation with thyroid cancer risk, were collected in this meta-analysis. Overall, RASSF1A promoter methylation significantly increased the risk of thyroid cancer (total, OR=8.27, CI=4.38-15.62,
conclusionThis meta-analysis confirms that RASSF1A promoter methylation is a risk factor for thyroid tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.